. Author manuscript; available in PMC: 2014 Aug 14.

Published in final edited form as: Lancet Glob Health. 2014 Apr 8;2(5):e267–e277. doi: 10.1016/S2214-109X(14)70032-4

Table 5.

Summary of incidence results across all African sites.

Subgroup	# Incident samples		Incidence		Intervention Effect	95% CI	p-value
Subgroup	CBVCT	SVCT	CBVCT	SVCT	Intervention Effect	95% CI	p-value
All participants	205	240	1•52	1•81	0•86	0•73–1•02	0•082
Analysis by gender
Women	142	161	2•06	2•42	0•88	0•73–1•06	0•17
Men	63	79	0•95	1•19	0•81	0•57–1•15	0•19
Analysis by age
18–24 years	125	134	1•65	1•76	0•98	0•80–1•22	0•86
25–32 years	80	105	1•38	1•90	0•75	0•54–1•04	0•078
Analysis by gender and age
Women, age 18–24 years	96	96	2•50	2•55	1•00	0•78–1•28	0•98
Men, age 18–24 years	29	38	0•76	0•98	0•95	0•64–1•40	0•69
Women, age 25–32 years	46	65	1•54	2•29	0•70	0•54–0•90	0•0085
Men, age 25–32 years	34	40	1•20	1•46	0•78	0•41–1•47	0•39

Incident samples: This indicates the number of samples from HIV-infected individuals that were classified as MAA positive (excluding samples with antiretroviral drugs detected), as well as samples HIV-infected individuals with acute or early infection.

Incidence: Annual rate in %; calculated across the African sites.

Intervention effect: Relative risk of HIV infection (CBVCT vs. SVCT); weighted average of incidence ratios for 17 community pairs.

95% CI: 95% confidence interval for intervention effect.

p-value: p-value for the hypothesis of no intervention effect on incidence.